Eleclazine and RAN reduced the AF window and AF burden in association with the inhibition of both endogenous and enhanced atrial late INa with half maximal inhibitory concentrations (IC50) of 1.14 and 9.78 μM and 0.94 and 8.31 μM, respectively [75]. This evidence concerns the gene RAN and atrial fibrillation.